VelosBio Appoints Paul Bavier as General Counsel
Sep 08, 2020 | 08:00 AMPDF Version
VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the appointment of Paul Bavier as General Counsel. Mr. Bavier will lead all legal and compliance-related functions at the Company.
Mr. Bavier has been practicing law for more than 20 years, most of which has been spent as an in-house attorney leading and building legal organizations within the biotechnology industry. Most recently, he served as General Counsel and Chief Compliance Officer for Avedro (now a subsidiary of Glaukos Corporation), where he was responsible for all legal, corporate secretary, and commercial compliance matters. Prior to Avedro, Mr. Bavier spent nine years as General Counsel and Secretary, in roles of increasing responsibility, at Biodel Inc. from 2007 to 2016. He began his legal career as a corporate attorney at Ropes and Gray, a Boston-based, top-tier national law firm.
“We are delighted to welcome Paul as our General Counsel, as we continue to expand and strengthen our executive leadership team,” said Dave Johnson, Chief Executive Officer at VelosBio. “Paul brings extensive legal expertise and an impressive industry track record as a business leader supporting biotech companies throughout all stages of growth. He will be invaluable as we advance our pipeline of ROR1-directed therapeutics to improve the lives of patients with cancer.”
“I am honored and excited to join VelosBio at this point of rapid growth as the Company executes on its strategy of delivering a pipeline of potentially transformative therapies in oncology. Dave has attracted an impressive and seasoned team of industry veterans to his leadership team, and I look forward to contributing to the company’s continued growth,” said Paul Bavier, General Counsel, VelosBio.
Mr. Bavier holds a J.D. degree from University of Michigan School of Law, and a B.A. in International Politics and Economics from Middlebury College. He is a member of the State Bar of Massachusetts and the State Bar of Connecticut.
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need. VelosBio is headquartered in San Diego. For more information, please visit www.velosbio.com.